Inhibition of urothelial carcinoma through targeted type I interferon-mediated immune activation
Type I interferon (IFN-I) has potent anti-tumor effects against urothelial carcinoma (UC) and may be an alternative treatment option for patients who do not respond to Bacillus Calmette-Guerin. However, the mechanisms that mediate the IFN-I-stimulated immune responses against UC have yet to be eluci...
Main Authors: | Devin Plote, Woonyoung Choi, Sharada Mokkapati, Debasish Sundi, James E Ferguson, Jon Duplisea, Nigel R. Parker, Seppo Yla-Herttuala, SUO CTC Bladder Committee, David McConkey, Kimberly S. Schluns, Colin P. Dinney |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2019-05-01
|
Series: | OncoImmunology |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/2162402X.2019.1577125 |
Similar Items
-
Lentiviral interferon: A novel method for gene therapy in bladder cancer
by: Sharada Mokkapati, et al.
Published: (2022-09-01) -
Interferon gene therapy with nadofaragene firadenovec for bladder cancer: from bench to approval
by: Alberto Martini, et al.
Published: (2023-08-01) -
Fibroblast growth factor receptors-1 and -3 play distinct roles in the regulation of bladder cancer growth and metastasis: implications for therapeutic targeting.
by: Tiewei Cheng, et al.
Published: (2013-01-01) -
AAV2 and AAV9 tropism and transgene expression in the mouse eye and major tissues after intravitreal and subretinal delivery
by: Sanna Koponen, et al.
Published: (2023-07-01) -
Therapeutic Potential of VEGF-B in Coronary Heart Disease and Heart Failure: Dream or Vision?
by: Rahul Mallick, et al.
Published: (2022-12-01)